Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and Insmed (NASDAQ:INSM – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Profitability
This table compares Nurix Therapeutics and Insmed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
| Insmed | -76.94% | -123.94% | -44.30% |
Volatility & Risk
Nurix Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
| Insmed | 1 | 0 | 22 | 2 | 3.00 |
Nurix Therapeutics currently has a consensus target price of $34.21, suggesting a potential upside of 31.39%. Insmed has a consensus target price of $205.52, suggesting a potential upside of 69.14%. Given Insmed’s stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Nurix Therapeutics.
Earnings and Valuation
This table compares Nurix Therapeutics and Insmed”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $83.98 million | 32.18 | -$264.46 million | ($3.45) | -7.55 |
| Insmed | $606.42 million | 43.76 | -$1.28 billion | ($4.11) | -29.56 |
Nurix Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Insmed beats Nurix Therapeutics on 8 of the 13 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
